(original) (raw)

TY - JOUR AU - El-Zawahry, Ahmed AU - McKillop, John AU - Voelkel-Johnson, Christina PY - 2005 DA - 2005/01/07 TI - Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts JO - BMC Cancer SP - 2 VL - 5 IS - 1 AB - Prostate cancer is a significant health problem among American men. Treatment strategies for androgen-independent cancer are currently not available. Tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) is a death receptor ligand that can induce apoptosis in a variety of cancer cell lines, including androgen-independent PC3 prostate carcinoma cells. In vitro, TRAIL-mediated apoptosis of prostate cancer cell lines can be enhanced by doxorubicin and correlates with the downregulation of the anti-apoptotic protein c-FLIP. This study evaluated the effects of doxorubicin on c-FLIP expression and tumor growth in combination with Apo2L/TRAIL in a xenograft model. SN - 1471-2407 UR - https://doi.org/10.1186/1471-2407-5-2 DO - 10.1186/1471-2407-5-2 ID - El-Zawahry2005 ER -